Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival

Bone Marrow Transplantation volume 41, pages 267–273 (2008)Cite this article

Abstract

The aim of this study was to evaluate the effects and kinetics of IgG levels after allogeneic stem cell transplantation (SCT). This study retrospectively examines 179 consecutive patients undergoing SCT between 1995 and 2002. Diagnoses included acute and chronic leukemia (n=136), solid tumors (n=11), other malignancies (n=16) and non-malignant diseases (n=16). Standard myeloablative conditioning was given to 146 patients, and 33 patients received reduced intensity conditioning. Serum samples for measurement of IgG levels were collected 3, 6 and 12 months after SCT, and then yearly. IgG levels increased after SCT throughout the study period. Factors that were associated with low IgG levels after SCT were acute graft-versus-host disease (GVHD), patient age ⩽30 years, female donor-to-male recipient, not receiving anti-thymocyte globulin and type of GVHD prophylaxis. Compared to patients with moderately low or normal levels as measured twice during the first year after transplantation, patients with low IgG levels (<4 g/l) showed a decreased survival rate (54 vs 71%, P=0.04) and an increased incidence of transplant-related mortality (27 vs 9%, P<0.01). IgG levels generally increase after SCT. Persistent low levels of IgG are a risk factor for death after SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Raaphorst FM . Reconstitution of the B cell repertoire after bone marrow transplantation does not recapitulate human fetal development. Bone Marrow Transplant 1999; 24: 1267–1272.

    Article  CAS  PubMed  Google Scholar 

  2. Paulin T, Ringdén O, Nilsson B . Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317–328.

    CAS  PubMed  Google Scholar 

  3. Storek J, Saxon A . Reconstitution of B cell immunity following bone marrow transplantation. Bone Marrow Transplant 1992; 9: 395–408.

    CAS  PubMed  Google Scholar 

  4. Atkinson K . Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209–226.

    CAS  PubMed  Google Scholar 

  5. Ringdén O, Witherspoon R, Storb R, Ekelund E, Thomas ED . B cell function in human marrow transplant recipients assessed by direct and indirect hemolysis-in-gel assays. J Immunol 1979; 123: 2729–2734.

    PubMed  Google Scholar 

  6. Omazic B, Hentschke P, Nasman-Bjork I, Mattsson J, Oxelius V-A, Ringdén O et al. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens. Scand J Immunol 2005; 61: 72–81.

    Article  CAS  PubMed  Google Scholar 

  7. Storek J, Wells D, Dawson MA, Storer B, Maloney DG . Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 489–491.

    Article  CAS  PubMed  Google Scholar 

  8. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA . Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75: 1583–1586.

    CAS  PubMed  Google Scholar 

  9. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44–53.

    CAS  PubMed  Google Scholar 

  10. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayiannis P, Griffiths PD et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339–343.

    Article  CAS  PubMed  Google Scholar 

  11. Storek J, Viganego F, Dawson MA, Herremans MMPT, Boeckh M, Flowers MED et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 2003; 101: 3319–3324.

    Article  CAS  PubMed  Google Scholar 

  12. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455–464.

    CAS  PubMed  Google Scholar 

  13. Olerup O, Zetterquist H . HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 h: an alternative to serological DR typing in clinical practice including donor–recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225–235.

    Article  CAS  PubMed  Google Scholar 

  14. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelöv L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.

    CAS  PubMed  Google Scholar 

  15. Svenberg P, Remberger M, Svennilson J, Mattsson J, Leblanc K, Gustafsson B et al. Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. Biol Blood Marrow Transplant 2004; 10: 877–882.

    Article  PubMed  Google Scholar 

  16. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O . Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823–830.

    Article  CAS  PubMed  Google Scholar 

  17. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  18. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253–261.

    Article  CAS  PubMed  Google Scholar 

  19. Mattsson J, Uzunel M, Brune M, Hentschke P, Barkholt L, Stierna U et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001; 115: 935–944.

    Article  CAS  PubMed  Google Scholar 

  20. Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221–226.

    PubMed  Google Scholar 

  21. Storb R, Deeg H, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Pharm G. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  22. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.

    CAS  PubMed  Google Scholar 

  23. Yun Z, Lewensohn-Fuchs I, Ljungman P, Ringholm L, Jonsson J, Albert J . A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods 2003; 110: 73–79.

    Article  CAS  PubMed  Google Scholar 

  24. Ljungman P, Griffiths P, Paya C . Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094–1097.

    Article  PubMed  Google Scholar 

  25. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78–83.

    PubMed  Google Scholar 

  26. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217–223.

    Article  CAS  PubMed  Google Scholar 

  27. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  28. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  29. Pettit SJ, Bourne H, Spickett GP . Survey of infection in patients receiving antibody replacement treatment for immune deficiency. J Clin Pathol 2002; 55: 577–580.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Roifman CM, Levison H, Gelfand EW . High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987; 1: 1075–1077.

    Article  CAS  PubMed  Google Scholar 

  31. Lum LG . Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 659–675.

    Article  CAS  PubMed  Google Scholar 

  32. Witherspoon RP, Storb R, Ochs HD, Fluornoy N, Kopecky KJ, Sull Deeg KM et al. Recovery of antibody production in human allogenic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58: 360–368.

    CAS  PubMed  Google Scholar 

  33. Näsman Björk I, Fesel C, Brissac C, Lundkvist I . Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogenic bone marrow transplantation. Scand J Immunol 1999; 50: 73–82.

    Article  PubMed  Google Scholar 

  34. Saral R . The role of immunoglobulin in bone marrow transplantation. Transplant Proc 1991; 23: 2128–2132.

    CAS  PubMed  Google Scholar 

  35. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation? N Engl J Med 1990; 323: 705–712.

    Article  CAS  PubMed  Google Scholar 

  36. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12–18.

    Article  CAS  PubMed  Google Scholar 

  37. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglund H, Winiarski J . Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60: 1225–1230.

    Article  CAS  PubMed  Google Scholar 

  38. Phillips NE, Parker DC . Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol 1984; 132: 627–632.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Swedish Cancer Society (0070-B03-17XBC), the Children's Cancer Foundation (03/039, 02/074), the Swedish Research Council (K2003-32X-05971-23A), the Stockholm Cancer Society, the Swedish Medical Society, the Tobias Foundation and the Karolinska Institutet.

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    A-C Norlin, D Sairafi, J Mattsson, O Ringdén & M Remberger

  2. Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    D Sairafi, J Mattsson, O Ringdén & M Remberger

  3. Department of Hematology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    P Ljungman

Authors
  1. A-C Norlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Sairafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Mattsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Remberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A-C Norlin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norlin, AC., Sairafi, D., Mattsson, J. et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41, 267–273 (2008). https://doi.org/10.1038/sj.bmt.1705892

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705892

Keywords

This article is cited by

Search

Advanced search

Quick links